Trna gene replacement therapy for trna-synthetase related charcot-marie-tooth disorder

Active Project Grant Awarded Last action

Award ID
R61NS136651
Recipient
Awarding agency
Obligated
$1,271,545

Award facts

Completion date 83% complete
Originally
Place of performance
Bar Harbor, ME 04609, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Charcot-marie-tooth disease (CMT) is a collection of inherited peripheral neuropathies with a cumulative incidence of ~1:2500 people. There is no approved treatment for any of the 100 genetic subtypes of CMT, presenting a large unmet clinical need. Charcot-marie-tooth type 2D is caused by dominant mutations in glycyl trna synthetase (gars), encoding the enzyme that charges glycine onto its cognate trnas during translation. Our working model for the disease mechanism is that the mutant enzyme binds its trna substrate, but does not release IT to the ribosome, effectively sequestering the substrate. This results in ribosome stalling at glycine codons and activation of the integrated stress response. Support for this mechanism comes from genetic studies in drosophila and mouse models of CMT2D, in which transgenic overexpression of trnaglygcc was able to effectively suppress the neuropathy phenotype. In preliminary studies, we have reproduced this result using AAV9 to deliver trnagly genes to three different CMT2D mouse models. Glycine has four codons (GGC, GGG, GGA, and GGU), and therefore four potential anticodons (GCC, CCC, UCC, and ACC respectively, though ACC is likely a nonfunctional trna). We made four AAV9 vectors expressing each trnagly anticodon driven by a poliii U6 promoter. We found that GCC was highly effective, almost completely suppressing the neuropathy phenotype even in mice with a severe allele of gars. Vectors expressing CCC and UCC were intermediate in efficacy, and ACC was ineffective (as anticipated). This profile of efficacy correlates with trna abundance and codon usage, and suggests we are replacing the sequestered substrates of gars with the aavs. In the R61 phase of this proposal we will optimize the vector payload (aim 1) and capsid (aim 2), and in the R33 phase (aim 3), we will use this optimized vector in rigorous preclinical studies in mouse models of CMT2D. In aim 1 (R61), we will construct an AAV9 vector that carries all three effective trnagly genes (GCC, CCC, UCC) in a single vector. We will compare this against GCC alone, which was very effective. In aim 2 (R61), we will recreate the U6-GCC vector in a macpns capsid in an attempt to create a vector that is effective with systemic delivery, rather than dosing directly into the nervous system. We will compare the macpns-GCC vector to AAV9-GCC. In aim 3 (R33), we will test the optimized vector (GCC or combined trnaglys, AAV9 or macpns) in two mouse models of CMT2D. We will also allow treated mice to age to show the perdurance of the effect, and we will examine the effects of treating after the onset of neuropathy. The successful completion of these aims will show the in vivo efficacy of an optimized gene therapy treatment for CMT2D in preclinical studies in mouse models. This will position US for further translational research and IND-enabling studies through mechanisms such as the blueprint neurotherapeutics network for biologicals.

Transactions

Action Obligated Date
Amendment $0
Amendment $411,015
Amendment -$12,709
Amendment -$12,709
Amendment $442,974
Original award $442,974

Subawards

Subrecipient Amount Awarded
Research Institute At Nationwide Children's Hospital The Harper lab will design, synthesize and perform in vitro screening of all tRNAGLY vectors. In addition, the Harper lab will generate pro-viral AAV… $107,244
Research Institute At Nationwide Children's Hospital $107,244

Quick answers

Who received award R61NS136651?

R61NS136651 was awarded to Jackson Laboratory by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on July 1, 2024.

How much is award R61NS136651 worth?

$1,271,545 has been obligated on R61NS136651.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login